Last Updated: October 2, 2026

CANAGLIFLOZIN Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Canagliflozin patents expire, and when can generic versions of Canagliflozin launch?

Canagliflozin is a drug marketed by Apotex and Aurobindo Pharma Ltd and is included in two NDAs.

The generic ingredient in CANAGLIFLOZIN is canagliflozin. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Canagliflozin

A generic version of CANAGLIFLOZIN was approved as canagliflozin by APOTEX on April 14^th, 2026.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for CANAGLIFLOZIN?
What are the global sales for CANAGLIFLOZIN?
What is Average Wholesale Price for CANAGLIFLOZIN?

Summary for CANAGLIFLOZIN

US Patents:	0
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANAGLIFLOZIN

Paragraph IV (Patent) Challenges for CANAGLIFLOZIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKANA	Tablets	canagliflozin	100 mg and 300 mg	204042	10	2017-03-29

US Patents and Regulatory Information for CANAGLIFLOZIN

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	CANAGLIFLOZIN	canagliflozin	TABLET;ORAL	210449-001	Apr 14, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aurobindo Pharma Ltd	CANAGLIFLOZIN	canagliflozin	TABLET;ORAL	210386-002	Apr 20, 2026		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Apotex	CANAGLIFLOZIN	canagliflozin	TABLET;ORAL	210449-002	Apr 14, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aurobindo Pharma Ltd	CANAGLIFLOZIN	canagliflozin	TABLET;ORAL	210386-001	Apr 20, 2026		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.